A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer

Background: Cabozantinib targets tyrosine kinases including MET, vascular endothelial growth factor (VEGF) receptor 2, and rearranged during transfection (RET). Differentiated thyroid cancer (DTC) is a tumor type that may be sensitive to cabozantinib. Therefore, we evaluated cabozantinib in a cohort...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cabanillas, Maria E., Brose, Marcia S., Holland, Jaymes, Ferguson, Kimberly C., Sherman, Steven I.
Formato: Artigo
Lenguaje:Inglês
Publicado: Mary Ann Liebert, Inc. 2014
Materias:
Thyroid Cancer and Nodules
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4195402/
https://ncbi.nlm.nih.gov/pubmed/25102375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2014.0125
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares